 |
 |
|||||||||
 |
| Home | Medi News | Medical Tidbits | Interesting Topics | Ask a Question | |
|
|
|||||||||
|
| Home | Medi News | Medical Tidbits | Interesting Topics | Ask a Question | |
 |
Exelon Improves Activities Of Daily Living In Alzheimer’s Patients | |
| Home Diseases / Conditions Medical Tidbits Interesting Topics Nutrition Altenative Systems Medical Wonders Interesting Questions Medi News |
Data
presented Saturday at the 52nd annual meeting of the
Gerontological Society of America suggest that Rivastigmine tartrate (Exelon®), an investigational, new
generation cholinesterase inhibitor, may be effective in
enhancing activities of daily living in patients with
mild to moderately severe Alzheimer’s disease. Exelon has also shown efficacy in cognition (memory) and global functioning including behavior. Significantly more patients treated with Exelon demonstrated increased abilities to dress appropriately, eat properly, use common household items, walk safely, tell time and show interest in hobbies. The compound is being developed by Novartis Pharmaceuticals and is currently under review with the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease. |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|